1. Home
  2. UEIC vs LPCN Comparison

UEIC vs LPCN Comparison

Compare UEIC & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$4.31

Market Cap

53.0M

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.30

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
LPCN
Founded
1986
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.0M
61.8M
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
UEIC
LPCN
Price
$4.31
$2.30
Analyst Decision
Hold
Hold
Analyst Count
1
1
Target Price
$3.50
N/A
AVG Volume (30 Days)
28.4K
867.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
23.78
46.18
EPS
N/A
N/A
Revenue
$368,288,000.00
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.69
$1.81
52 Week High
$7.50
$12.37

Technical Indicators

Market Signals
Indicator
UEIC
LPCN
Relative Strength Index (RSI) 54.79 29.55
Support Level $4.33 N/A
Resistance Level $4.62 $3.40
Average True Range (ATR) 0.19 0.34
MACD -0.02 -0.06
Stochastic Oscillator 52.73 6.41

Price Performance

Historical Comparison
UEIC
LPCN

About UEIC Universal Electronics Inc.

Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: